AQ128
Inflammatory Disease (unspecified)
PreclinicalActive
Key Facts
About Aqilion
Aqilion is a publicly traded Swedish biotech specializing in early-stage drug development for chronic inflammatory and autoimmune diseases. The company operates a virtual or asset-centric model, advancing a small pipeline of internally developed small molecule candidates, with lead programs AQ280 and AQ128 poised for clinical development. Its strategy is to de-risk innovative science through preclinical and early clinical proof-of-concept before seeking partnerships or out-licensing to larger pharmaceutical companies for late-stage development and commercialization.
View full company profile